Revenue
2022
2023
2024
2025
Genflow Biosciences plc (GENF)
Price£0.02175Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 | N/A |
| Gross profit | £585,607 | £320,471 | N/A | N/A | N/A |
| Research & development | £1.1M | £1.2M | £1.2M | £724,465 | N/A |
| Operating expenses | £2.0M | £1.9M | £1.9M | £1.3M | N/A |
| Operating income | −£1.4M | −£1.6M | −£1.9M | −£1.3M | N/A |
| EBITDA | −£1.4M | −£1.6M | −£1.9M | −£1.3M | N/A |
| Net income | −£1.4M | −£1.6M | −£1.9M | −£1.3M | −£988,195 |
| Basic EPSper basic share | -£0.33 | -£0.48 | -£0.01 | -£0.00 | N/A |
| Diluted EPSper diluted share | -£0.00 | -£0.00 | -£0.01 | -£0.00 | N/A |
Owners
Reported major voting-rights holders
12.13%of voting rights
Jonathan Mark SwannNotified Jan 23, 2026
View holders
| Holder | Voting rights |
|---|---|
| 12.13%Jan 23, 2026 · 59.86M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA voting-rights notice ↗Updated Oct 21, 2026